Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT04855656 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT04855656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Lead sponsor
Debiopharm International SA
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2021
Completion date
June 30, 2028
Enrollment
464 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor